Gliflozins – an attractive opportunity for early market access
This whitepaper outlines the Dr. Reddy's Gliflozins API portfolio that has been developed through the integrated understanding of IP, regulatory affairs, process development (API & formulation), and API manufacturing in order to ensure early entry into the market. The integrated approach allows for development of an optimal synthesis route in the context of the IP situation.
Read our latest whitepaper on this topic by filling the contact form below.
You can also explore our Gliflozins offering by clicking on the links below:
Canagliflozin (Amorphous): https://api.drreddys.com/product/canagliflozin-amorphous
Dapagliflozin (Amorphous): https://api.drreddys.com/product/dapagliflozin-amorphous
Empagliflozin (Amorphous): https://api.drreddys.com/product/empagliflozin-amorphous